The effect of dietary n-3 fatty acids on serum concentrations of C-reactive protein: A dose-response study

British Journal of Nutrition

Volumn 89, Issue 4, 2003, Pages 517-522

  Madsen, Trine ^a   Christensen, Jeppe H ^a   Blom, Mogens ^b   Schmidt, Erik B ^a  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b NORTH DENMARK REGIONAL HOSPITAL   (Denmark)

Author keywords

C reactive protein; Fatty acids; Fish oil; Inflammation

Indexed keywords

C REACTIVE PROTEIN; FISH OIL; OLIVE OIL; OMEGA 3 FATTY ACID; PLACEBO;

ADULT; ARTICLE; CELL COMPOSITION; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET SUPPLEMENTATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FAT CONTENT; FAT INTAKE; FATTY ACID ANALYSIS; FEMALE; GRANULOCYTE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OUTCOMES RESEARCH; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; THROMBOCYTE; VOLUNTEER;

ADULT; ANALYSIS OF VARIANCE; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; DIETARY FATS, UNSATURATED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0038325709     PISSN: 00071145     EISSN: None     Source Type: Journal    
DOI: 10.1079/BJN2002815     Document Type: Article

References (31)

1. Belluzzi A, Boschi S, Brignola C, Munarini A, Cariani G & Miglio F (2000) Polyunsaturated fatty acids and inflammatory bowel disease. American Journal of Clinical Nutrition 71, 339S-342S.
2. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G & Maseri A (1999) Elevated levels of C-reactive protein at discharge in pateints with unstable angina predict recurrent instability. Circulation 99, 855-860.
3. Brown AJ, Pang E & Roberts DC (1991) Persistent changes in the fatty acid composition of erythrocyte membranes after moderate intake of n-3 polyunsaturated fatty acids: Study design implications. American Journal of Clinical Nutrition 54, 668-673.
4. Calder PC (2001) Polyunsaturated fatty acids, inflammation, and immunity. Lipids 36, 1007-1024.
5. Campos SP & Baumann H (1992) Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Molecular and Cellular Biology 12, 1789-1797.
6. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R & Heinrich PC (1990) Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12, 1179-1186.
7. Caughey GE, Mantzioris E, Gibson RA, Cleland LG & James MJ (1996) The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. American Journal of Clinical Nutrition 63, 116-122.
8. Chan DC, Watts GF, Barrett PH, Beilin LJ & Mori TA (2002) Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clinical Chemistry 48, 877-883.
9. Christensen JH, Christensen MS, Dyerberg J & Schmidt EB (1999) Heart rate variability and fatty acid content of blood cell membranes: A dose-response study with n-3 fatty acids. American Journal of Clinical Nutrition 70, 331-337.
10. De Caterina R, Liao JK & Libby P (2000) Fatty acid modulation of endothelial activation. American Journal of Clinical Nutrition 71, 213S-223S.
11. Erlandsen EJ & Randers E (2000) Reference interval for serum C-reactive protein in healthy blood donors using the Dade Behring N Latex CRP mono assay. Scandinavian Journal of Clinical Laboratory Investigation 60, 37-43.
12. Ernst E, Saradeth T & Achhammer G (1991) n-3 Fatty acids and acute-phase proteins. European Journal of Clinical Investigation 21, 77-82.
13. James MJ & Cleland LG (1997) Dietary n-3 fatty acids and therapy for rheumatoid arthritis. Seminars in Arthritis and Rheumatism 27, 85-97.
14. James MJ, Gibson RA & Cleland LG (2000) Dietary polyunsaturated fatty acids and inflammatory mediator production. American Journal of Clinical Nutrition 71, 343S-348S.
15. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL & Pepys MB (1999) C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99, 237-242.
16. Lee TH & Austen KF (1986) Arachidonic acid metabolism by the 5-lipoxygenase pathway, and the effects of alternative dietary fatty acids. Advances in Immunology 39, 145-175.
17. Macy EM, Hayes TE & Tracy RP (1997) Variability in the measurement of C-reactive protein in healthy subjects: Implications for reference intervals and epidemiological applications. Clinical Chemistry 43, 52-58.
18. Madsen T, Skou HA, Hansen VE, Fog L, Christensen JH, Toft E & Schmidt EB (2001) C-reactive protein, dietary n-3 fatty acids, and the extent of coronary artery disease. American Journal of Cardiology 88, 1139-1142.
19. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF & Mullington JM (2001) Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clinical Chemistry 47, 426-430.
20. Nielsen GL, Faarvang KL, Thomsen BS, Teglbjaerg KL, Jensen LT, Hansen TM, Lervang HH, Schmidt EB, Dyerberg J & Ernst E (1992) The effects of dietary supplementation with n-3 polyunsaturated fatty acids in patients with rheumatoid arthritis: A randomized, double blind trial. European Journal of Clinical Investigation 22, 687-691.
21. Ridker PM (2001) High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103, 1813-1818.
22. Ridker PM, Cushman M, Stampfer MJ, Tracy RP & Hennekens CH (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. New England Journal of Medicine 336, 973-979.
23. Rifai N, Tracy RP & Ridker PM (1999) Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clinical Chemistry 45, 2136-2141.
24. Ross R (1999) Atherosclerosis - An inflammatory disease. New England Journal of Medicine 340, 115-126.
25. Schmidt EB (1997) n-3 Fatty acids and the risk of coronary heart disease. Danish Medical Bulletin 44, 1-22.
26. Schmid EB & Dyerberg J (1989) n-3 Fatty acids and leucocytes. Journal of Internal Medicine 225, 151S-158S.
27. Schmidt EB, Pedersen JO, Varming K, Ernst E, Jersild C, Grunnet N & Dyerberg J (1991) n-3 Fatty acids and leukocyte chemotaxis. Effects in hyperlipidemia and dose-response studies in healthy men. Arteriosclerosis and Thrombosis 11, 429-435.
28. Simopoulos AP (1999) Essential fatty acids in health and chronic disease. American Journal of Clinical Nutrition 70, 560S-569S.
29. Steel DM & Whitehead AS (1994) The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunology Today 15, 81-88.
30. Tataru MC, Heinrich J, Junker R, Schulte H, Von Eckardstein A, Assmann G & Koehler E (2000) C-reactive protein and the severity of atherosclerosis in myocardial infarction patients with stable angina pectoris. European Heart Journal 21, 1000-1008.
31. Toss H, Lindahl B, Siegbahn A & Wallentin L (1997) Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 96, 4204-4210.